Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

Novartis

Status and phase

Completed

Phase 2

Phase 1

Conditions

Coronary Heart Disease

Treatments

Drug: APL180

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00568594

CAPL180A2201

Details and patient eligibility

About

The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of APL018 in patients with CHD

Enrollment

176 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Male and female healthy volunteers (ages 18-55 years) and patients with CHD (ages 18 to 75 years) on stable statin therapy for at least 8 weeks, with normal liver and kidney function.
Women who are post-menopausal, surgically sterile, or practicing effective contraception. Additional birth control details to be provided at screening.
Body mass index (BMI) must be within the range of 20 to 35 for CHD patients or CHD equivalents.
Clinical CHD:
Myocardial infarction (MI), angina, revascularization (e.g. CABG, stent) at least 6 months prior to inclusion
CHD equivalents:
symptomatic carotid artery disease (e.g. transient ischemic attack or stroke of carotid origin) or peripheral artery disease or abdominal aortic aneurysm or Diabetes Mellitus (HbA1c ≤9)
20% 10 year risk of CHD (Framingham point score: ≥16 (men), ≥23 (women))
Other clinical forms of atherosclerotic disease including >50 percent stenosis on angiography or ultrasound
Male subjects, when sexually active, using one form of highly effective contraception (e.g. condom)

Exclusion Criteria for both healthy volunteers and patients:

Smokers (use of tobacco products in the previous 3 months). Smokers who report cigarette use of more then 10 cigarette per day or have a urinary cotinine level greater then 500 ng/ml.
Pregnancy.
Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Significant illness within two weeks prior to dosing.
Significant illness within two weeks prior to dosing.
A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome.
History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug or any allergic reaction to prior receipt of protein therapies or vaccines.
Presence of NYHA Class III or IV CHF or unstable angina pectoris.
MI or within angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to dosing.
Use of certain medications prohibited by the protocol.
Uncontrolled diabetes (HbA1c > 9).
Uncontrolled hypertension (Systolic BP >160 mm Hg and/or Diastolic BP >100 mmHg on two consecutive measurements).
Liver or kidney disease confirmed by abnormal lab values or function.
Serum creatine kinase CK (CPK) total > 2x.
CHD equivalent patients with a history of early positive exercise stress test.